**Nimenrix® (meningococcal groups A, C, W-135 and Y conjugate vaccine) eModule Series for Healthcare Professionals**

**Module 4 – Knowledge Check**

1. What is the volume of a dose of reconstituted Nimenrix®?
   1. 0.2 ml
   2. 0.5 ml
   3. 0.8 ml
   4. 1.0 ml

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. True or false: A booster dose of Nimenrix® is only appropriate for individuals who have previously received primary vaccination with Nimenrix®.

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. True or false: Nimenrix® is a conjugate vaccine that can help protect against the *N. meningitidis* serogroups A, C, W-135 and Y.

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. Nimenrix® has demonstrated immunogenicity in which age groups?
   1. Babies (<6 weeks)
   2. Babies and toddlers (≥6 weeks – 23 months)
   3. Children (2 – 10 years)
   4. Adolescents (11 – 17 years)
   5. Adults (18 – 55 years)
   6. Elderly (≥56 years)

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. Which of the following are very common (≥1/10) side effects that have been reported following Nimenrix® vaccination in age groups 6 weeks to 55 years? *Select all that apply*
   1. Irritability
   2. Drowsiness
   3. Dizziness
   4. Fever
   5. Insomnia
   6. Loss of appetite

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. Which of the following are common (≥1/100 to <1/10) side effects that have been reported following Nimenrix® vaccination in age groups 6 weeks to 55 years? *Select all that apply*
   1. Diarrhoea
   2. Pruritus
   3. Vomiting
   4. Myalgia
   5. Hypoaesthesia
   6. Insomnia

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. True or false: Vaccination should not be deferred in the presence of a minor infection such as a cold.

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**ANSWERS**

1. What is the volume of a dose of reconstituted Nimenrix®?
   1. 0.2 ml
   2. 0.5 ml
   3. 0.8 ml
   4. 1.0 ml

Answer: b1

1. True or false: A booster dose of Nimenrix® is only appropriate for individuals who have previously received primary vaccination with Nimenrix®.

Answer: false1

1. True or false: Nimenrix® is a conjugate vaccine that can help protect against the *N. meningitidis* serogroups A, C, W-135 and Y.

Answer: true1

1. Nimenrix® has demonstrated immunogenicity in which age groups?
   1. Babies (<6 weeks)
   2. Babies and toddlers (≥6 weeks – 23 months)
   3. Children (2 – 10 years)
   4. Adolescents (11 – 17 years)
   5. Adults (18 – 55 years)
   6. Elderly (≥56 years)

Answer: b, c, d, e, f1

1. Which of the following are very common (≥1/10) side effects that have been reported following Nimenrix® vaccination in age groups 6 weeks to 55 years? *Select all that apply*
   1. Irritability
   2. Drowsiness
   3. Dizziness
   4. Fever
   5. Insomnia
   6. Loss of appetite

Answer: a, b, d, f1

1. Which of the following are common (≥1/100 to <1/10) side effects that have been reported following Nimenrix® vaccination in age groups 6 weeks to 55 years? *Select all that apply*
   1. Diarrhoea
   2. Pruritus
   3. Vomiting
   4. Myalgia
   5. Hypoaesthesia
   6. Insomnia

Answer: a, c1

1. True or false: Vaccination should not be deferred in the presence of a minor infection such as a cold.

Answer: True1

**Reference**

1. Pfizer Limited. Nimenrix® Summary of Product Characteristics. February 2021.

